Purchase this article with an account.
Timothy Lai, Kyoko Ohno-Matsui, Tien Y Wong, Paolo Lanzetta, Stefan Pilz, Nikol Heinrichs, RADIANCE study group; Comparison of visual acuity outcomes and ranibizumab treatment exposure in East-Asian and Caucasian patients with visual impairment due to myopic CNV: a RADIANCE study subgroup analysis. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4959.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Pathologic myopia (PM) is one of the leading causes of blindness. Visual impairment due to PM is more common in East-Asians (12.2-27.4%) than Caucasians (5.8-7.8%); with approximately 10% of East-Asians and 5% of Caucasians developing myopic choroidal neovascularization (CNV). Currently it is unclear whether there is difference in treatment for myopic CNV between East-Asians and Caucasians. The RADIANCE study demonstrated that ranibizumab treatment led to rapid and sustained best-corrected visual acuity (BCVA) improvement in patients with visual impairment due to myopic CNV. We performed a post-hoc, exploratory subgroup analysis of treatment outcome and exposure comparing East-Asian and Caucasian patients of this study.
In the RADIANCE study patients (N=277) were randomized 2:2:1 to Group (G)-1 (ranibizumab treatment guided by VA stabilization), G2 (ranibizumab treatment guided by disease activity), or G3 (vPDT and as of Month [M] 3, ranibizumab and/or vPDT at investigator’s discretion). Of the randomized patients, BCVA outcomes and treatment exposure of the East-Asian (n=35) and Caucasian (n=70) patients of G2 (which was the basis for the proposed and approved label for treatment of visual impairment due to myopic CNV) were analyzed. Key outcome measures were mean change in BCVA from baseline and number of injections up to 12M.
Baseline demographics and ocular characteristics of the study eye analyzed were well balanced across the subgroups (East-Asians vs Caucasians); mean age (54.2 vs 58.0 years); gender (female: 80.0% vs 75.7%), baseline BCVA (54.2 vs 55.9 letters), axial length (28.4 vs 28.9 mm), refraction sphere (10.7 vs 11.8 diopters) and lesion size (2.8 vs 2.5 mm2). At M12, the East-Asian patients gained 16.1 early treatment diabetic retinopathy study (ETDRS) letters with a median of 2.0 (mean: 2.9) injections while the Caucasian patients gained 14.1 ETDRS letters with a median of 3.0 (mean: 3.8) injections (Table).
East-Asian patients with myopic CNV showed numerically higher BCVA gains with one less injection than Caucasians over 12 months. Further analysis is required to explore underlying reasons and the potential predictors of BCVA outcomes and number of injections in these ethnic groups.
This PDF is available to Subscribers Only